Leukemia Home > Campath and CLL

The prescription drug Campath® (alemtuzumab) is licensed to treat a type of leukemia known as B-cell chronic lymphocytic leukemia (B-CLL). It comes as an injection that is given for 12 weeks.
Campath belongs to a group of drugs called monoclonal antibodies, which means it is approved for use alone (as a single agent) to treat people with B-CLL. It may reduce symptoms of leukemia and extend the time a person is able to live without their condition getting worse. Some people may experience a complete disappearance of their leukemia symptoms. However, not everyone will respond to the medication in the same way.
(To learn more about how this drug works to treat B-CLL, click Campath Uses. This article also explains whether it can be given to children and older adults, and lists some off-label uses.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.